Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.42Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.Company Guidance
Strong Clinical Momentum and Multiple Near-Term Catalysts
Company highlighted a catalyst-rich 12 months with multiple expected readouts: KOASTAL-2/3 topline data in Q2 2026, NMRA-511 MAD extension data in H2 2026, NMRA-898 MAD data in H2 2026, and planned clinical entry for NMRA-215 in Q1 2027 (now delayed due to tox retest). Management emphasized differentiated mechanisms and brain-penetrant chemistry across the pipeline.
NMRA-511 (vasopressin 1a antagonist) — Positive Phase Ib Prespecified Analysis
Phase Ib prespecified analysis in 53 patients with NPI-AA ≥4 showed clinically meaningful benefit with a Cohen's d effect size of 0.32–0.34 on CMAI total score (similar magnitude to Rexulti). Safety/tolerability favorable with no reported somnolence or sedation. Company will run a MAD extension (data expected H2 2026) and plans Phase II initiation in Q1 2027.
Navacaprant (kappa opioid antagonist) — Phase III Programs Fully Enrolled
KOASTAL-2 and KOASTAL-3 are fully enrolled with >400 patients in each study. Joint topline readout expected in Q2 2026. Study design included optimizations after KOASTAL-1 (enhanced monitoring, screening tools, site selection), resulting in ~10% higher screen-fail rate versus KOASTAL-1, intended to improve dataset quality.
M4 PAM Franchise — NMRA-898 Selected as Lead with Compelling Early Human PK/PD
NMRA-898 chosen as lead for schizophrenia based on Phase I data: human half-life ~80–100 hours (supports once-daily dosing), dose-proportional exposures with low variability, predicted free brain exposure above in vitro M4 EC50, and on-target pharmacodynamic heart rate changes indicative of engagement. MAD data expected H2 2026.
NMRA-215 (CNS NLRP3 inhibitor) — Class-Leading DIO Mouse Data
12-week diet-induced obesity (DIO) mouse study showed supportive results: dose-dependent, class-leading weight loss as monotherapy and additive effects in combination with semaglutide; switching paradigms preserved weight loss (NMRA-215 maintained semaglutide-like loss when switched at week 8). Management referenced ~20–25% relative weight-loss effects in prior studies and ~23% combo reduction referenced in Q&A modeling.
Financial Position — Cash on Hand and Runway
As of Dec 31, 2025, cash, cash equivalents and marketable securities totaled $182.5 million. Management expects this cash position to support operations into Q3 2027. Total net loss for 2025 was comparable to 2024.
NMRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NMRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | $2.33 | $1.93 | -17.17% |
Nov 06, 2025 | $2.62 | $2.58 | -1.53% |
Aug 06, 2025 | $1.59 | $1.65 | +3.77% |
May 12, 2025 | $0.69 | $0.68 | -1.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neumora Therapeutics, Inc. (NMRA) report earnings?
Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Neumora Therapeutics, Inc. (NMRA) earnings time?
Neumora Therapeutics, Inc. (NMRA) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMRA EPS forecast?
Currently, no data Available